Northwire Canada EditionMonday, July 13, 2026
Sign inSubscribe
Northwire
⌕
GLDN 0.055 +0.0% BRON 0.040 +0.0% BTO 5.43 −0.7% ESK 0.365 −2.7% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0% GLDN 0.055 +0.0% BRON 0.040 +0.0% BTO 5.43 −0.7% ESK 0.365 −2.7% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0%
Regulatory

NervGen Pharma Begins Trading on Nasdaq Today

By The Northwire Desk — AI Analysis Jan 08, 2026 · 06:30 NGEN · 7.82 Nervgen Pharma Corp.
NGEN · Price

Executive Summary

  • NervGen Pharma Corp.’s common shares have been approved for listing on Nasdaq and will begin trading under the ticker “NGEN” on the same day.
  • The Nasdaq listing follows recent positive Phase 1b/2a CONNECT SCI study data, positioning the company for late‑stage development of its lead candidate NVG‑291.
  • Management expects the listing to enhance visibility, liquidity, and broaden the shareholder base, supporting continued clinical advancement and potential future financing.

Key Details

  • Nasdaq Listing Approval: NervGen’s common shares are now listed on Nasdaq (symbol “NGEN”) as of Jan 8 2026.
  • Clinical Milestone Reference: The announcement references expanded Phase 1b/2a CONNECT SCI data released 24 Nov 2025, showing durable functional improvements in chronic spinal‑cord injury patients.
  • Regulatory Pathway Updates: FDA Type C meeting (Sept 2025) confirmed multiple approval pathways; an End‑of‑Phase 2 meeting is scheduled for early 2026 to align on development and registration strategy for NVG‑291.
  • Strategic Impact Statement: CEO Adam Rogers highlighted that Nasdaq listing will improve market visibility, liquidity, and diversify the shareholder base, supporting long‑term value creation as the company advances toward a potential first‑in‑class pharmacologic therapy for SCI.
  • Future Clinical Plans: Ongoing enrollment of sub‑acute SCI patients in the CONNECT study; preparation underway for a Phase 3 trial in chronic SCI.

Notable Quotes

“A listing on Nasdaq marks a defining moment in NervGen’s evolution… we believe this listing will enhance visibility in the marketplace, improve liquidity, broaden and diversify our shareholder base, and ultimately drive long‑term shareholder value…” – Adam Rogers, MD, Interim CEO, NervGen Pharma.

Read the original news release →

More from Nervgen Pharma Corp.

Apr 07, 2026 · 07:30

FDA aligns on Phase 3 design, clearing the path for NVG‑291’s registrational trial

Other Mar 31, 2026 · 07:45

Clinical Validation Confirmed, Capital Runway Tightens Ahead of Phase 3 Pivot

Earnings Mar 12, 2026 · 16:15

NervGen Pharma Announces Voluntary Delisting from TSX Venture Exchange

Financings Feb 09, 2026 · 07:00

NervGen Pharma Appoints Adam Rogers as Chief Executive Officer to Continue Leading the Company's Growth and Execution of Its Mission in Spinal Cord Injury

Other Nov 24, 2025 · 07:06

NervGen Pharma Reports Third Quarter Financial Results and Provides Business Updates

Earnings Nov 24, 2025 · 07:02

NervGen Pharma Announces Expanded CONNECT SCI Study Data Demonstrating Unprecedented Durable Improvement in Function, Independence, and Quality of Life in Chronic Spinal Cord Injury

Other